About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Ajanta Pharma Ltd.
Change Company
BSE Code
532331
ISIN Demat
INE031B01049
Book Value
282.56
NSE Code
AJANTPHARM
Dividend Yield %
1.79
Market Cap
356211.83
P/E
41.72
EPS
68.36
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
10-Sep-2024
Ajanta Pharma informs about disclosure
23-Aug-2024
Ajanta Pharma informs about loss of share certifi...
21-Aug-2024
Ajanta Pharma informs about disclosure
08-Aug-2024
Ajanta Pharma informs about participation in inve...
31-Jul-2024
Ajanta Pharma moves up on reporting 18% rise in Q...
30-Jul-2024
Ajanta Pharma reports 18% rise in Q1 consolidated...
17-Jul-2024
Ajanta Pharma informs about board meeting
11-Jul-2024
Ajanta Pharma informs about compliances-certifica...
18-Jun-2024
Ajanta Pharma informs about annual report and BRS...
17-Jun-2024
Ajanta Pharma informs about newspapers publicatio...
04-Jun-2024
Ajanta Pharma informs about disclosure
15-Apr-2024
Ajanta Pharma informs about compliance certificate
30-Mar-2024
Ajanta Pharma informs about disclosure
25-Jan-2024
Ajanta Pharma informs about update on board meeti...
25-Jan-2024
Ajanta Pharma submits intimation of record date
Page
1
of
1
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.